Researchers found that over half of the clinics offered compounded variations of weight loss drugs combined with B vitamins, while a smaller percentage offered levocarnitine and glycine
There are also limitations to the study from the Mayo Clinic researchers
In the lifestyle counseling alone group, changes were +0.01 ng/mL for CTX (95% CI: 0.05 to 0.07) and 0.58 mg/mL for P1NP (95% CI: 6.69 to 5.52)]
The SURPASS program, which targeted patients with type 2 diabetes [29, 36,37,38,39,40,41,42], and the SURMOUNT program, which included individuals with obesity but without diabetes [43,44,45], both reported clinically significant reductions in body weight
The clinical maturation of GLP-1 receptor agonists demonstrates that such features can be reshaped through long-acting formulations, exposure smoothing, biased agonism, and indication-specific dosing rather than being avoided altogether